赛诺菲获得欧盟批准使用Rezurock治疗慢性移植对宿主疾病. Sanofi receives EU approval for Rezurock to treat chronic graft-versus-host disease.

赛诺菲获得欧洲批准,用于治疗成人和12岁以上儿童的慢性移植对宿主疾病. Sanofi received European approval for Rezurock to treat chronic graft-versus-host disease in adults and children over 12. 这为其他治疗没有反应的患者提供了一个新的选择. This offers a new option for patients who have not responded to other treatments. 经过欧洲药物管理局的积极建议和临床试验数据显示高反应率,该公司获得了许可. The authorization follows a positive recommendation from the European Medicines Agency and clinical trial data showing a high response rate.